Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
How to watch the 2025 Macy's Thanksgiving Day Parade for free - 26 Useful Home Espresso Machines
- 3Remarkable Spots for Hot Air Swelling All over The Planet
- 4'Always put others first': IDF reservist who died while on leave saves four with organ transplants
- 5The Beginning Of The End For Fossil Fuels Can Start In Colombia
- Instructions to Expand Your Smash 1500's Presentation: Tips and Deceives
- ISS astronaut snaps stunning nighttime photo of Florida and Cuba | Space photo of the day for Dec. 29, 2025
- Starfront Observatories: A haven for distant stargazers
- Australian State Triggers Emergency Powers Amid Fuel Crisis
- UN torture cm'tee report flags Israel for allegedly mistreating journalists, detainees, ex-MAG
- Tire Brands for Senior Drivers: Guaranteeing Security and Solace
- Who plays Moana in the live-action remake? What to know about Catherine Lagaʻaia.
- Peloton recalls more than 800,000 bikes after broken seat posts injure users
- Moon rocket and weather are on NASA's side for the first astronaut launch in decades
